Galectin Therapeutics Inc SEC filings GALT
Galectin Therapeutics Inc has 1,000 filings in SEC EDGAR's recent list, going back to Oct 18, 2011. Its latest annual report, Form ARS, was filed on Oct 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 14, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 10-Q | Quarterly report | Nov 13, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 16, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 17, 2021 | Mar 31, 2021 |
| 10-Q | Quarterly report | Nov 9, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Aug 10, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 11, 2020 | Mar 31, 2020 |
| 10-Q | Quarterly report | Nov 12, 2019 | Sep 30, 2019 |
| 10-Q | Quarterly report | Aug 9, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 10, 2019 | Mar 31, 2019 |
| 10-Q | Quarterly report | Nov 13, 2018 | Sep 30, 2018 |
| 10-Q/A | Amended quarterly report | Sep 28, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Aug 14, 2018 | Jun 30, 2018 |
| 10-Q | Quarterly report | May 11, 2018 | Mar 31, 2018 |
| 10-Q | Quarterly report | Nov 7, 2017 | Sep 30, 2017 |
| 10-Q | Quarterly report | Aug 14, 2017 | Jun 30, 2017 |
| 10-Q | Quarterly report | May 15, 2017 | Mar 31, 2017 |
| 10-Q | Quarterly report | Nov 8, 2016 | Sep 30, 2016 |
| 10-Q | Quarterly report | Aug 9, 2016 | Jun 30, 2016 |
| 10-Q | Quarterly report | May 10, 2016 | Mar 31, 2016 |
| 10-Q | Quarterly report | Nov 9, 2015 | Sep 30, 2015 |
| 10-Q | Quarterly report | Aug 10, 2015 | Jun 30, 2015 |
| 10-Q | Quarterly report | May 11, 2015 | Mar 31, 2015 |
| 10-Q | Quarterly report | Nov 10, 2014 | Sep 30, 2014 |
| 10-Q | Quarterly report | Aug 7, 2014 | Jun 30, 2014 |
| 10-Q | Quarterly report | May 13, 2014 | Mar 31, 2014 |
| 10-Q | Quarterly report | Nov 12, 2013 | Sep 30, 2013 |
| 10-Q | Quarterly report | Aug 14, 2013 | Jun 30, 2013 |
| 10-Q | Quarterly report | May 10, 2013 | Mar 31, 2013 |
| 10-Q | Quarterly report | Nov 9, 2012 | Sep 30, 2012 |
| 10-Q | Quarterly report | Aug 10, 2012 | Jun 30, 2012 |
| 10-Q | Quarterly report | May 11, 2012 | Mar 31, 2012 |
| 10-Q | Quarterly report | Nov 10, 2011 | Sep 30, 2011 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Norcross, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133416
- Former names
- PRO PHARMACEUTICALS INC (until May 26, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.